

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Abbisko Cayman Limited
和譽開曼有限責任公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2256)

PROPOSED CHANGE OF COMPANY NAME

The board of directors (the “**Board**”) of Abbisko Cayman Limited (the “**Company**”) proposes to change the English name of the Company from “Abbisko Cayman Limited” to “Abbisko Medicine Co., Ltd.” and the dual foreign name in Chinese of the Company from “和譽開曼有限責任公司” to “和譽醫藥有限責任公司” (the “**Proposed Change of Company Name**”).

CONDITIONS OF THE PROPOSED CHANGE OF COMPANY NAME

The Proposed Change of Company Name is subject to the following conditions:

- (i) the passing of a special resolution by the shareholders of the Company (the “**Shareholders**”) to approve the Proposed Change of Company Name at the extraordinary general meeting of the Company (the “**EGM**”); and
- (ii) the issuance of a certificate of incorporation on change of name by the Registrar of Companies in the Cayman Islands with respect to the Proposed Change of Company Name.

Subject to the satisfaction of the above conditions, the Proposed Change of Company Name will take effect from the date on which the Registrar of Companies in the Cayman Islands issues the certificate of incorporation on change of name in respect of the Proposed Change of Company Name. Thereafter, the Company will carry out all necessary filing procedures with the Companies Registry in Hong Kong under the Companies Ordinance (Chapter 622 of the Laws of Hong Kong).

REASON FOR THE PROPOSED CHANGE OF COMPANY NAME

The Board considers that the Proposed Change of Company Name will more accurately reflect the Company’s actual business operations and our current stage of development. This will not only strengthen the Company’s corporate image but also reaffirm the Company’s vision and commitment to developing innovative medicines to address patients’ unmet medical needs. Accordingly, the Board considers the Proposed Change of Company Name to be in the best interests of the Company and the Shareholders as a whole.

EFFECT OF THE PROPOSED CHANGE OF COMPANY NAME

The Proposed Change of Company Name will not affect any of the rights of the Shareholders and the trading of the shares (the “**Shares**”) of the Company on the Main Board of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”). Moreover, the Proposed Change of Company Name will not, of itself, affect the rights of any Shareholders or the Company’s daily business operation and its financial position.

All existing share certificates of the Company bearing the existing names of the Company will, after the Proposed Change of Company Name becomes effective, continue to be valid evidence of title to the Shares and will continue to be valid for trading, settlement, registration and delivery purposes. As such, no arrangement will be made for the exchange of the existing share certificates of the Company for the new share certificates bearing the Company’s new name as a result of the Proposed Change of Company Name. Once the Proposed Change of Company Name has become effective, share certificates of the Company will only be issued in the new name of the Company.

GENERAL

At the EGM, a special resolution will be proposed for the Shareholders to consider and, if thought fit, approve the Proposed Change of Company Name. A circular containing, among other things, further information relating to the Proposed Change of Company Name, together with a notice convening the EGM will be despatched to the Shareholders in due course.

The Company will make further announcement(s) to inform the Shareholders of the poll results of the EGM and the effective date of the Proposed Change of Company Name.

For the avoidance of doubt, the English and Chinese stock short names of the Company for trading in the Shares on the Main Board of the Stock Exchange will remain unchanged as “ABBISKO-B” and “和譽-B”, respectively. The stock code of the Company will remain unchanged as “2256”. The Company’s website will also remain unchanged.

By order of the Board
Abbisko Cayman Limited
Dr. Xu Yao-Chang
Chairman

Shanghai, August 24, 2026

As at the date of this announcement, the Board comprises Dr. Xu Yao-Chang, Dr. Yu Hongping and Dr. Ji Jing as executive directors; and Dr. Sun Piaoyang, Mr. Sun Hongbin and Ms. Chui Hoi Yam as independent non-executive directors.